NASDAQ:LMNX - Luminex Stock Price, News, & Analysis

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Monday, February 11th. Shareholders of record on Thursday, March 21st will be given a dividend of $0.06 per share on Thursday, April 11th. This represents a $0.24 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Wednesday, March 20th. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Monday, February, 4th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.08. The medical instruments supplier earned $81.10 million during the quarter, compared to analysts' expectations of $80.76 million. Luminex had a return on equity of 4.61% and a net margin of 5.81%. The company's revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter last year, the company earned $0.20 earnings per share. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Luminex.

Luminex issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $337-343 million, compared to the consensus revenue estimate of $333.79 million.Luminex also updated its FY 2018 guidance to EPS.

4 Wall Street analysts have issued 1-year target prices for Luminex's shares. Their predictions range from $22.00 to $33.00. On average, they anticipate Luminex's share price to reach $27.00 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for Luminex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

News articles about LMNX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.

Some companies that are related to Luminex include Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Nevro (NVRO), Atrion (ATRI), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX) and K2M Group (KTWO).

Luminex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.65%), Dimensional Fund Advisors LP (4.41%), Acadian Asset Management LLC (3.23%), Northern Trust Corp (2.12%), Bessemer Group Inc. (1.94%) and Bank of New York Mellon Corp (1.42%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., D. E. Shaw & Co. Inc., State Board of Administration of Florida Retirement System, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Hancock Whitney Corp and PNC Financial Services Group Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., First Trust Advisors LP, Thomson Horstmann & Bryant Inc., Martingale Asset Management L P, Geode Capital Management LLC, Barclays PLC, Dimensional Fund Advisors LP and Rhumbline Advisers. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $26.04.

Luminex has a market capitalization of $1.16 billion and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.50 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 922 workers across the globe.

The official website for Luminex is http://www.luminexcorp.com.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]